Axsome Therapeutics reported strong revenue growth and product performance, supported by strategic commercial execution and a robust R&D pipeline. However, increased expenses and ongoing net losses present financial challenges.

Company Guidance

In its third-quarter 2025 earnings call, Axsome Therapeutics reported substantial financial growth and shared strategic guidance for its product portfolio and R&D pipeline. The company achieved a total revenue of $171 million, marking a 63% increase year-over-year, with AUVELITY generating $136.1 million in net product sales, SUNOSI contributing $32.8 million, and SYMBRAVO adding $2.1 million in its first full quarter post-launch. Axsome's gross-to-net discounts for AUVELITY and SUNOSI were in the high 40% range, expected to rise to the low 50% range in Q4. The company highlighted its R&D advancements, including a supplemental NDA for AXS-05 targeting Alzheimer's disease agitation and an anticipated NDA submission for AXS-12 for narcolepsy by year-end. Axsome plans to initiate multiple Phase III trials for various indications, including ADHD and fibromyalgia, before the year's end. The firm is optimistic about further expanding its commercial reach and advancing its late-stage pipeline, projecting a path toward cash flow positivity with its current cash reserves of $325.3 million.

Record Revenue Growth

Total revenue for the third quarter reached $171 million, representing a 63% increase year-over-year. AUVELITY net product sales were $136.1 million, up 69% versus last year.

Strong Product Performance

SUNOSI net product revenues increased by 35% year-over-year, with consistent growth in prescriptions. SYMBRAVO completed its first full quarter, generating $2.1 million in net sales and over 3,300 new patients started therapy.

Advancement in R&D Pipeline

Submitted supplemental NDA for AXS-05 in Alzheimer's disease agitation. Preparing NDA submission for AXS-12 in narcolepsy. Multiple Phase III trials planned for ADHD, binge eating disorder, and shift work disorder.

Commercial Strategy Success

AUVELITY prescriptions grew 46% year-over-year with increased coverage to 85% of all lives. Initiated direct-to-consumer advertising campaign, boosting new patient starts.

Axsome Therapeutics (AXSM) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AXSM Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 02, 2026	2025 (Q4)	-0.56 / -	-1.54	―	―	―
Nov 03, 2025	2025 (Q3)	-0.86 / -0.94	-1.34	29.85% (+0.40)
Aug 04, 2025	2025 (Q2)	-1.05 / -0.97	-1.67	41.92% (+0.70)
May 05, 2025	2025 (Q1)	-1.35 / -1.22	-1.44	15.28% (+0.22)
Feb 18, 2025	2024 (Q4)	-1.00 / -1.54	-2.08	25.96% (+0.54)
Nov 12, 2024	2024 (Q3)	-1.38 / -1.34	-1.32	-1.52% (-0.02)
Aug 05, 2024	2024 (Q2)	-1.31 / -1.67	-1.54	-8.44% (-0.13)	―
May 06, 2024	2024 (Q1)	-1.21 / -1.44	-0.26	-453.85% (-1.18)	―
Feb 20, 2024	2023 (Q4)	-1.17 / -2.08	-1.41	-47.52% (-0.67)
Nov 06, 2023	2023 (Q3)	-1.20 / -1.32	-1.07	-23.36% (-0.25)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AXSM Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 03, 2025	$134.99	$135.75	+0.56%
Aug 04, 2025	$103.02	$106.54	+3.42%
May 05, 2025	$112.21	$116.49	+3.81%
Feb 18, 2025	$131.15	$128.09	-2.33%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Axsome Therapeutics Inc (AXSM) report earnings?

Axsome Therapeutics Inc (AXSM) is schdueled to report earning on Mar 02, 2026, Before Open (Confirmed).

What is Axsome Therapeutics Inc (AXSM) earnings time?

Axsome Therapeutics Inc (AXSM) earnings time is at Mar 02, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is AXSM EPS forecast?

AXSM EPS forecast for the fiscal quarter 2025 (Q4) is -0.56.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing